In connection with the Company's first-time requirement to prepare consolidated financial statements for the 2026 financial year, the Supervisory Board of Cantourage Group SE resolved at its meeting today to transition the Company's consolidated financial reporting from German GAAP (HGB) to International Financial Reporting Standards (IFRS).

A preliminary reconciliation of the 2025 consolidated financial figures from HGB to IFRS indicates significant positive effects on earnings and equity. These effects primarily result from differences in the accounting treatment of goodwill and share-based compensation plans.

A detailed pro forma comparison of the 2025 consolidated financial figures under HGB and IFRS will be published on the Company's website in early November 2026, following the completion of the audit of the 2025 consolidated financial statements.

About Cantourage
Cantourage is a leading European company engaged in the production and distribution of medical cannabis preparations and cannabis-based pharmaceuticals. With an experienced management team and its “Fast Track Access” platform, Cantourage enables producers from around the world to access the growing European medical cannabis market faster, more easily and more cost-effectively by processing and distributing their cannabis raw materials and extracts. In doing so, Cantourage consistently ensures compliance with the highest European pharmaceutical quality standards.
The Company offers pharmaceutical-grade products across all relevant market segments: dried flower, extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt Stock Exchange on 11 November 2022 – DE000A3DSV01 (ISIN).
 

2418358  19-Oct-2026 CET/CEST